April 13, 2011 | Filed under: Health,News | Posted by:
The experimental oral multiple sclerosis (MS) drug laquinimod delayed disease progression, reduced relapse rates, and was safe and well tolerated by patients in a two-year study.
Posted by
on April 13, 2011. Filed under Health, News.
You can follow any responses to this entry through the RSS 2.0.
You can skip to the end and leave a response. Pinging is currently not allowed.
Posted by
on April 13, 2011. Filed under